Understanding the role of transmembrane 9 superfamily member 1 in bladder cancer pathogenesis

doi:10.5306/wjco.v15.i4.468

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (346)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

220

Sum=229

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=100

Publishing Process of This Article

Item

Count

Browse

Download

Sum=6

Apr 24, 2024 (publication date) through May 9, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Apr 24, 2024; 15(4): 468-471
Published online Apr 24, 2024. doi: 10.5306/wjco.v15.i4.468

Understanding the role of transmembrane 9 superfamily member 1 in bladder cancer pathogenesis

Venkata Krishna Vamsi Gade, Budhi Singh Yadav

Venkata Krishna Vamsi Gade, Department of Radiotherapy & Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India

Budhi Singh Yadav, Department of Radiotherapy & Oncology, Regional Cancer Centre, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India

Author contributions: Both the authors contributed equally by data collection, manuscript writing, editing and approval.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Budhi Singh Yadav, MD, Professor, Department of Radiotherapy & Oncology, Regional Cancer Centre, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. drbudhi@gmail.com

Received: December 20, 2023
Peer-review started: December 20, 2023
First decision: February 2, 2024
Revised: February 16, 2024
Accepted: March 6, 2024
Article in press: March 6, 2024
Published online: April 24, 2024

Core Tip

Core Tip: The scratch wound healing assay and transwell assay showed significantly improved cellular migration in the Transmembrane 9 superfamily member 1 (TM9SF1) overexpression group. TM9SF1 silencing inhibited proliferation, migration and invasion of bladder cancer (BC) cells. TM9SF1 can be used as a therapeutic molecular target. The importance of TM9SF1 as an oncogene and its use as a therapeutic target would ultimately depend on the prevalence of the mutation in BC tissues and replication of in vitro activity in tumour tissue.